Overture Life Appoints Matt Combs as Chief Commercial Officer to Lead IVF Automation Technology Expansion

Overture Life, a leader in automated IVF technology, has appointed Matthew Combs as Chief Commercial Officer to drive global expansion amid rising demand for IVF automation technology. Combs has over 15 years of experience in healthcare and medtech, including a stint at Butterfly Network, where he helped scale operations to $70 million in annual revenue. He will lead the commercialization of Overture's fertility technologies, including the ICSI.A and DaVitri, to meet growing clinic demand.

Overture Life, a pioneering company in automated IVF technology, has appointed Matthew Combs as its Chief Commercial Officer (CCO) to oversee the global expansion of its fertility technologies. This move comes amidst a surge in demand for IVF automation solutions worldwide, driven by increasing embryologist shortages and the need for more consistent and affordable IVF outcomes.

Combs brings over 15 years of experience in healthcare and medtech, with a notable stint at Butterfly Network where he helped scale operations to over $70 million in annual revenue. His appointment at Overture Life is expected to leverage his expertise in driving rapid revenue growth and scaling organizations, particularly in the medtech sector. Prior to joining Overture Life, Combs served as the Chief Growth Officer at Amalgam, where he led the market expansion of the company’s SaaS products. He has also held commercial leadership roles at Boston Scientific, Stryker, and FUJIFILM Sonosite.

Combs will focus on scaling Overture Life’s fertility technologies, including the ICSI.A, the world’s first robot for automated fertilization, and the DaVitri, for automated, consistent, high-quality vitrification that expands egg freezing beyond specialized IVF facilities. The appointment of Combs underscores Overture Life’s commitment to addressing real operational challenges faced by clinics, such as embryologist shortages and the need for more predictable IVF outcomes.

According to Hans Gangeskar, CEO of Overture Life, the demand for their technology is increasing exponentially, with clinics from various regions asking for access to their systems. Combs’s experience in scaling Butterfly Network into a public company is seen as a strategic asset for Overture Life as it transitions from proving its technology to scaling it globally.

Combs himself expressed excitement about the potential of Overture’s technology, comparing it to the early stages of Butterfly Network. He noted that IVF has been constrained by manual processes that create barriers to accessibility and consistency in performance. Overture’s automation addresses these challenges, providing clinics with a solution that can significantly improve operational efficiency and patient outcomes.

Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling. The company’s DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines.

References:
[1] https://www.businesswire.com/news/home/20250715897703/en/Overture-Life-Appoints-Former-Butterfly-Network-Executive-Matt-Combs-as-Chief-Commercial-Officer-to-Lead-Scale-up-of-IVF-Automation-Technology-as-Demand-Surges-Worldwide